August 11, 2020Open Access

Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas

Key Points

Key points are not available for this paper at this time.

Abstract

These findings suggest that the immune landscape of brain tumors are markedly different postimmunotherapy yet can still be targeted with immunotherapy.

Read Full Paperexternally

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Wildes et al. (Tue,) studied this question.

synapsesocial.com/papers/69e68f2120beb83f0968d39b https://doi.org/https://doi.org/10.1158/1078-0432.ccr-20-1065

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cancer immunoediting: from immunosurveillance to tumor escape2002 · 5,280 citations
2Immune Selection and Emergence of Aggressive Tumor Variants as Negative Consequences of Fas-Mediated Cytotoxicity and Altered IFN-γ-Regulated Gene Expression2005 · 38 citations
3Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation2003 · 1,578 citations
4PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?2017 · 383 citations
5EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss2013 · 292 citations